GRP
RARE icon

Global Retirement Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Global Retirement Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47K Buy
+134
New +$3.33K ﹤0.01% 3730
2025
Q4 		$1.2K Buy
52
+41
+373% +$1.35K ﹤0.01% 3853
2025
Q3 		$331 Sell
11
-34
-76% -$1.02K ﹤0.01% 3694
2025
Q2 		$1.64K Buy
+45
New +$1.62K ﹤0.01% 3308
2024
Q4 		$1.89K Hold
45
– – ﹤0.01% 3090
2024
Q3 		$2.5K Hold
45
– – ﹤0.01% 2863
2024
Q2 		$1.85K Hold
45
– – ﹤0.01% 2991
2024
Q1 		$2.1K Hold
45
– – ﹤0.01% 2733
2023
Q4 		$1.98K Buy
45
+8
+22% +$310 ﹤0.01% 2677
2023
Q3 		$1.27K Sell
37
-15
-29% -$594 ﹤0.01% 2702
2023
Q2 		$2.4K Hold
52
– – ﹤0.01% 2474
2023
Q1 		$2.25K Sell
52
-3
-5% -$129 ﹤0.01% 2462
2022
Q4 		$2.55K Buy
55
+31
+129% +$1.22K ﹤0.01% 2269
2022
Q3 		$1K Sell
24
-4
-14% -$206 ﹤0.01% 2556
2022
Q2 		$2K Hold
28
– – ﹤0.01% 2252
2022
Q1 		$1K Buy
+28
New +$1.95K ﹤0.01% 2490

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Global Retirement Partners's RARE Position: Q2 2026 in Review

Global Retirement Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 134 shares worth $4.47K. The stake represents ﹤0.01% of the portfolio and ranks #3730 among its holdings. This is a return to the name: Global Retirement Partners previously reported a position in RARE as recently as Q4 2025.

Global Retirement Partners first reported a position in RARE in Q1 2022 and has held it in 16 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Global Retirement Partners held 134 shares of Ultragenyx Pharmaceutical worth $4.47K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Global Retirement Partners position in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Global Retirement Partners's portfolio in Q2 2026, its #3730 holding.
  • Global Retirement Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and has held it in 16 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Global Retirement Partners's 13F filing for Q2 2026, filed 6 Aug 2026.